The UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the pharmaphorum podcast.
On it I spoke with Chris Molloy, who’s CEO at the UK’s Medicines Discovery Catapult, about the Catapult’s State of the Discovery Nation publication, a joint report with the UK’s biotech trade body the BioIndustry Association.
For episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to record a special roundtable episode in Philadelphia with the International AIDS Vaccine Initiative (IAVI).
For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.
The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.
Re-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AMR).
In episode 9 of the pharmaphorum podcast Alan Westwood explains the research behind Matoke’s SurgihoneyRO, an antimicrobial wound gel that has a CE mark in Europe, and how the company is taking that product’s reactive oxygen (RO) component to develop novel pharmaceutical antimicrobials.
Digital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which I visited GlaxoSmithKline at their Stockley Park base to speak with Kai Gait, a senior global digital strategy director at the company.
For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.